Recent Highlights:
- Asset-Focused Development Model: By combining focused and experienced teams with strategic support from Instil, Instil intends to establish a portfolio of asset-focused development subsidiaries. To accomplish this strategy, Instil intends to internally develop or in-license programs, building a diversified portfolio of development candidates.
- Cash Position: Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled approximately
$67 .1 million as ofSeptember 30, 2026 , which Instil expects will fund its current operating plan through 2027.
Third Quarter 2026 Financial and Operating Results:
As of
In-process research and development expenses were nil for the three and nine months ended
Research and development expenses were
General and administrative expenses were
Restructuring and impairment charges, net were a reversal of costs of
Net loss was
In preparing its third-quarter 2026 financial statements, Instil identified errors in previously issued financial statements relating to property taxes on its
Note Regarding Use of Non-GAAP Financial Measures
In this press release, Instil has presented certain financial information that has not been prepared in accordance with
About Instil Bio
Instil Bio, Inc. is a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs. For more information, visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding establishing a portfolio of asset-focused development subsidiaries, internally developing or in-licensing programs, and building a diversified portfolio of development candidates; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other macroeconomic factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC and Instil ’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
Media Relations:
Kimberly Ha
KKH Advisors
1-917-291-5744
kimberly.ha@kkhadvisors.com
SELECTED FINANCIAL DATA | |||||
| Selected Condensed Consolidated Balance Sheet Data (Unaudited; in thousands) | |||||
| Cash, cash equivalents, restricted cash, marketable securities and long-term investments | $ | 67,091 | $ | 76,295 | |
| Total assets | $ | 195,645 | $ | 204,515 | |
| Total liabilities | $ | 93,081 | $ | 91,844 | |
| Total stockholders’ equity | $ | 102,564 | $ | 112,671 | |
| Condensed Consolidated Statements of Operations (Unaudited; in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| In-process research and development | $ | — | $ | — | $ | — | $ | 10,000 | |||||||
| Research and development | 233 | 9,127 | 1,172 | 21,241 | |||||||||||
| General and administrative | 5,833 | 6,344 | 17,510 | 22,689 | |||||||||||
| Restructuring and impairment charges, net | (81 | ) | — | 1,092 | 16,622 | ||||||||||
| Total operating expenses | 5,985 | 15,471 | 19,774 | 70,552 | |||||||||||
| Loss from operations | (5,985 | ) | (15,471 | ) | (19,774 | ) | (70,552 | ) | |||||||
| Interest income | 615 | 893 | 1,925 | 3,112 | |||||||||||
| Interest expense | (1,554 | ) | (1,582 | ) | (4,688 | ) | (4,398 | ) | |||||||
| Other rental income | 2,697 | 2,691 | 8,090 | 8,076 | |||||||||||
| Gain on contract termination | — | — | 1,620 | — | |||||||||||
| Other (expense) income, net | (4 | ) | (118 | ) | (196 | ) | 267 | ||||||||
| Net loss | $ | (4,231 | ) | $ | (13,587 | ) | $ | (13,023 | ) | $ | (63,495 | ) | |||
| Net loss per share, basic and diluted | $ | (0.62 | ) | $ | (2.01 | ) | $ | (1.92 | ) | $ | (9.58 | ) | |||
| Weighted-average shares used in computing net loss per share, basic and diluted | 6,781,976 | 6,757,742 | 6,781,976 | 6,629,949 | |||||||||||
Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net loss | $ | (4,231 | ) | $ | (13,587 | ) | $ | (13,023 | ) | $ | (63,495 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense | 984 | 1,768 | 3,005 | 7,087 | |||||||||||
| Restructuring and impairment charges, net | (81 | ) | — | 1,092 | 16,622 | ||||||||||
| Non-GAAP net loss | $ | (3,328 | ) | $ | (11,819 | ) | $ | (8,926 | ) | $ | (39,786 | ) | |||
| Net loss per share, basic and diluted | $ | (0.62 | ) | $ | (2.01 | ) | $ | (1.92 | ) | $ | (9.58 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense per share | 0.15 | 0.26 | 0.44 | 1.07 | |||||||||||
| Restructuring and impairment charges, net per share | (0.01 | ) | — | 0.16 | 2.51 | ||||||||||
| Non-GAAP net loss per share, basic and diluted* | $ | (0.48 | ) | $ | (1.75 | ) | $ | (1.32 | ) | $ | (6.00 | ) | |||
| Weighted-average shares outstanding, basic and diluted | 6,781,976 | 6,757,742 | 6,781,976 | 6,629,949 | |||||||||||
* Non-GAAP net loss per share, basic and diluted may not total due to rounding.
Source: 